HTT and Huntington disease: VY-HTT01 (NCT04885114) was developed by Voyager Therapeutics and utilizes an AAV1 vector to deliver a genetic sequence into brain cells that produces a miRNA targeting HTT mRNA, which can decrease harmful HTT protein levels and potentially slow the progression of HD by preventing nerve cell death.